Premium
TAVR in bicuspid aortic valve stenosis: “We are not there yet” to draw final conclusions
Author(s) -
De Backer Ole,
Søndergaard Lars
Publication year - 2018
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/ccd.27606
Subject(s) - medicine , bicuspid aortic valve , stenosis , valve replacement , bicuspid valve , cardiology , randomized controlled trial
Key Points TAVR for bicuspid AS is not associated with excess mortality, but paravalvular leak and pacemaker implant is increased compared to tricuspid AS cohorts undergoing TAVR. Operators should weigh these potential complications against the clinical benefit obtained with TAVR for bicuspid AS patients at high surgical risk. A randomized controlled trial comparing TAVR with SAVR in younger, low‐surgical risk patients with—or at least not excluding—bicuspid AS is strongly needed.